SQZ Biotechnologies Co (SQZ Biotechnologies Co) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of SQZ Biotechnologies Co is: No Data: Cannot be evaluated.

Competitive Comparison of SQZ Biotechnologies Co's Risk Assessment

For the Biotechnology subindustry, SQZ Biotechnologies Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQZ Biotechnologies Co's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Risk Assessment falls into.

SQZ Biotechnologies Co (OTCPK:SQZB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

SQZ Biotechnologies Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472

Website

https://www.sqzbiotech.com

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

Executives

Richard Capasso	officer: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren	officer: Chief Medical Officer	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman	director, 10 percent owner	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j.	director	ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc.	10 percent owner	1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016	10 percent owner	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei	director, officer: President and CEO	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472